Laura Benjamin

Laura E. Benjamin has served as Chief Executive Officer of Myris Therapeutics (fka BioHybrid Solutions) since February 2024. Prior to this, she was its Executive Board Chair since 2023. Dr. Benjamin has also served as a member of the board of directors of Allarity Therapeutics since 2023. From 2016 until 2023, Dr. Benjamin founded and led OncXerna Therapeutics, Inc. as its Chief Executive Officer, where she raised more than $100 million, advanced two clinical programs, navicixizumab and bavituximab, and built the Xerna™ TME Panel, an RNA-based biomarker now licensed to Qiagen and Exact Sciences. From 2009 until 2016, Dr. Benjamin served as Vice President, Oncology Research at Eli Lilly and Company, first at ImClone Systems and then in the merged research organization, where she held key roles in advancing and launching multiple products, including Cyramza®, which is approved for gastric, colorectal, liver and lung cancers. Prior to her industry experience, Dr. Benjamin spent ten years on the faculty of the Department of Pathology at Harvard Medical School, during which time she served as Associate Director of the Center for Vascular Biology Research at Beth Israel Deaconess Medical Center and received the Harvard Medical School Excellence in Mentoring Award in 2009. Dr. Benjamin completed her postdoctoral training in cancer and vascular biology at Hadassah Hospital, and she received a Ph.D. in molecular cancer biology from the University of Pennsylvania and a B.A. in biology from Barnard College, Columbia University.